2/12/2013

Drugmakers have come under fire lately for six-figure annual pricing on some new drugs, and payers are beginning to push back. Instead of developing drugs for rare diseases as a way to stabilize profits, drugmakers should improve diagnostics and precision treatments, and should develop better treatments for diabetes, depression and other chronic diseases, says Alkermes CEO Richard Pops.

Full Story:
Xconomy

Related Summaries